Immunic, Inc. (IMUX) Free cash flow 2016–2025
Immunic, Inc. (IMUX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$86.0MFY2025 · since FY2016: -$36.3M → -$86.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$86.0M | -1.1% |
| FY2024 | -$85.0M | -19.5% |
| FY2023 | -$71.2M | -9.1% |
| FY2022 | -$65.3M | +21.7% |
| FY2021 | -$83.3M | -80.0% |
| FY2020 | -$46.3M | -61.8% |
| FY2019 | -$28.6M | -192.7% |
| FY2018 | -$9.8M | +76.2% |
| FY2017 | -$41.1M | -13.1% |
| FY2016 | -$36.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMUX financial trends
IMUX RevenueIMUX Net incomeIMUX Net marginIMUX Gross profitIMUX Gross marginIMUX Operating incomeIMUX Operating marginIMUX Operating cash flowIMUX Capital expendituresIMUX Return on equityIMUX Stock buybacksIMUX Dividends paidIMUX Total assetsIMUX Total liabilitiesIMUX Shareholders’ equityIMUX overview →